Endothelial cell effects of cytotoxics: balance between desired and unwanted effects.

[1]  S. Dimmeler,et al.  Endothelial Progenitor Cells: Characterization and Role in Vascular Biology , 2004, Circulation research.

[2]  S. Baruchel,et al.  Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  de Elisabeth G. E. Vries,et al.  Dose-finding and pharmacokinetic study of ABT-510 with gemcitabine and cisplatin in patients with advanced cancer , 2004 .

[4]  N. Weijl,et al.  Non-protein bound iron release during chemotherapy in cancer patients. , 2004, Clinical science.

[5]  P. Calabresi,et al.  Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice , 2004, Cancer Chemotherapy and Pharmacology.

[6]  Zhi-quan Wu,et al.  Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  A. Barqawi,et al.  Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma , 2003, Cancer.

[8]  W. Scheithauer,et al.  Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Kerbel,et al.  Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Fortier,et al.  Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  R. Kerbel,et al.  Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. , 2003, Cancer research.

[12]  Shahin Rafii,et al.  Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration , 2003, Nature Medicine.

[13]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[14]  Zvi Fuks,et al.  Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.

[15]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[16]  A. Dicker,et al.  Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere) , 2003, International journal of cancer.

[17]  Christie M. Orschell,et al.  Peripheral Blood “Endothelial Progenitor Cells” Are Derived From Monocyte/Macrophages and Secrete Angiogenic Growth Factors , 2003, Circulation.

[18]  P. Hahnfeldt,et al.  Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. , 2003, Journal of theoretical biology.

[19]  E. Papadimitriou,et al.  Amifostine Inhibits Angiogenesis in Vivo , 2003, Journal of Pharmacology and Experimental Therapeutics.

[20]  Ruud P. M. Dings,et al.  The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. , 2003, Cancer research.

[21]  H. Lennernäs,et al.  Chemotherapy and Antiangiogenesis , 2003, Acta oncologica.

[22]  J. Henkin,et al.  Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly , 2003, Anti-cancer drugs.

[23]  R. Kerbel,et al.  Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. , 2002, Cancer research.

[24]  R. Weichselbaum,et al.  Angiostatin potentiates cyclophosphamide treatment of metastatic disease , 2002, Cancer Chemotherapy and Pharmacology.

[25]  V. V. van Hinsbergh,et al.  Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[26]  B. Chabner.  Cytotoxic agents in the era of molecular targets and genomics. , 2002, The oncologist.

[27]  Robert Kiss,et al.  In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. , 2002, International journal of oncology.

[28]  R. Wenger,et al.  Cellular adaptation to hypoxia: O2‐sensing protein hydroxylases, hypoxia‐inducible transcription factors, and O2‐regulated gene expression , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  K. Alitalo,et al.  VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies , 2002, Nature Medicine.

[30]  E. Winer,et al.  2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Rafii,et al.  Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.

[32]  Terry L. Smith,et al.  Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  L. Ellis,et al.  Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. , 2002, Cancer research.

[34]  J. Redondo,et al.  Doxorubicin Induces Apoptosis and CD95 Gene Expression in Human Primary Endothelial Cells through a p53-dependent Mechanism* , 2002, The Journal of Biological Chemistry.

[35]  G. Peters,et al.  Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  N. Pavlakis,et al.  Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Hicklin,et al.  Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.

[38]  C. Twelves.  Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. , 2002, European journal of cancer.

[39]  D. Ribatti,et al.  Docetaxel versus paclitaxel for antiangiogenesis. , 2002, Journal of hematotherapy & stem cell research.

[40]  A. Goldhirsch,et al.  Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  R. Kerbel,et al.  Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  C. Kahn,et al.  Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis , 2002, Science.

[43]  J. Joseph,et al.  Doxorubicin-induced Apoptosis Is Associated with Increased Transcription of Endothelial Nitric-oxide Synthase , 2001, The Journal of Biological Chemistry.

[44]  N. Bouck,et al.  Thrombospondin‐1, vascular endothelial growth factor and fibroblast growth factor‐2 are key functional regulators of angiogenesis in the prostate , 2001, The Prostate.

[45]  A. Zwinderman,et al.  Chemotherapy-induced chromosomal damage in peripheral blood lymphocytes of cancer patients supplemented with antioxidants or placebo. , 2001, Mutation research.

[46]  O. Stoeltzing,et al.  Endothelial survival factors as targets for antineoplastic therapy. , 2001, Cancer journal.

[47]  E. Van Cutsem,et al.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  A. Adamou,et al.  Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  P. Black,et al.  Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. , 2001, Cancer research.

[50]  R. Colman,et al.  Kininostatin, an Angiogenic Inhibitor, Inhibits Proliferation and Induces Apoptosis of Human Endothelial Cells , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[51]  J. Hainsworth,et al.  Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  D. McDonald,et al.  Time course of endothelial cell proliferation and microvascular remodeling in chronic inflammation. , 2001, The American journal of pathology.

[53]  P. Ratcliffe,et al.  Activation of the HIF pathway in cancer. , 2001, Current opinion in genetics & development.

[54]  A. Mailloux,et al.  Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. , 2001, European journal of cell biology.

[55]  A. Goldhirsch,et al.  Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.

[56]  E Harrison,et al.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Y. Tanaka,et al.  Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  G. Sledge,et al.  Redefining the target: chemotherapeutics as antiangiogenics. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  E. Voest,et al.  The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. , 2001, Seminars in oncology.

[60]  W. Oster,et al.  Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. , 2000, International journal of hematology.

[61]  E. D. de Vries,et al.  Long-term chemotherapy-related cardiovascular morbidity. , 2000, Cancer treatment reviews.

[62]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[63]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[64]  E Glatstein,et al.  High-time chemotherapy or high time for low dose. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  A. Gown,et al.  A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[66]  M. Runge,et al.  Doxorubicin-Induced Cardiomyopathy , 2000 .

[67]  R. Kerbel,et al.  'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. , 2000, European journal of cancer.

[68]  L. Ellis,et al.  Chemotherapeutic drugs—more really is not better , 2000, Nature Medicine.

[69]  Gabriele Bergers,et al.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.

[70]  Peter Bohlen,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .

[71]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[72]  D J van Veldhuisen,et al.  Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  R. Kerbel.  Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[74]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[75]  R Folberg,et al.  Vasculogenic mimicry and tumor angiogenesis. , 2000, The American journal of pathology.

[76]  J. Aarbakke,et al.  Microvascular Perturbations in Rats Receiving the Maximum Tolerated Dose of Methotrexate or Its Major Metabolite 7-Hydroxymethotrexate , 2000, Ultrastructural pathology.

[77]  D. Ribatti,et al.  Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine , 1999 .

[78]  J. Schiller,et al.  Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  H. Choy.  Taxanes in combined-modality therapy for solid tumors. , 1999, Oncology.

[80]  R. Bast,et al.  Phase II study of vinorelbine administered by 96‐hour infusion in patients with advanced breast carcinoma , 1999, Cancer.

[81]  H. Ishitsuka,et al.  Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′‐deoxy‐5‐fluorouridine by cyclophosphamide in mammary tumor models , 1999, International journal of cancer.

[82]  K. Friedrichs,et al.  Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[84]  C. Shapiro,et al.  Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  I. Blasig,et al.  Protective effects of the thiophosphate amifostine (WR 2721) and a lazaroid (U83836E) on lipid peroxidation in endothelial cells during hypoxia/reoxygenation. , 1998, Biochemical pharmacology.

[86]  S. Aamdal,et al.  Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  P. Singal,et al.  Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.

[88]  J. Hoffmann,et al.  Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[89]  E. Keshet,et al.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.

[90]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[91]  K. Pritchard,et al.  Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. , 1997, Biochemistry.

[92]  A. Küttner,et al.  Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. , 1997, Circulation.

[93]  A. Grandi,et al.  Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  F. Chauvin,et al.  The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. , 1997, British journal of clinical pharmacology.

[95]  C. Bokemeyer,et al.  Evaluation of long-term toxicity after chemotherapy for testicular cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  G. Viale,et al.  The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[97]  M. Cwikiel,et al.  The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[98]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[99]  J. Glick,et al.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  G. Hortobagyi,et al.  Vinorelbine: an overview. , 1996, Cancer treatment reviews.

[101]  G. Peters,et al.  Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice. , 1995, European journal of cancer.

[102]  S. Akiyama,et al.  Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. , 1995, Cancer research.

[103]  J. Verweij,et al.  Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  D. Doll,et al.  Vascular toxicity associated with chemotherapy and hormonotherapy. , 1994, Current opinion in oncology.

[105]  Norbertus C. Robben,et al.  The syndrome of 5‐fluorouracil cardiotoxicity. An elusive cardiopathy , 1993, Cancer.

[106]  P. Soulié,et al.  Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  D. Doll,et al.  Vascular toxicity associated with antineoplastic agents. , 1992, Seminars in oncology.

[108]  A. Howell,et al.  Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. , 1992, European journal of cancer.

[109]  M. Lorenzato,et al.  The effects of 5-fluorouracil on contractility and oxygen uptake of the isolated perfused rat heart. , 1992, Anticancer research.

[110]  V Nehls,et al.  Heterogeneity of microvascular pericytes for smooth muscle type alpha- actin , 1991, The Journal of cell biology.

[111]  D. Carney,et al.  Thromboembolism. A complication of weekly chemotherapy in the treatment of non‐Hodgkin's lymphoma , 1990, Cancer.

[112]  M. Ro̸rth,et al.  Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[113]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[114]  T. Nomura,et al.  Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose , 1989, Cancer.

[115]  R. Saura,et al.  Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. , 1989, Arthritis and rheumatism.

[116]  A. V. van Oosterom,et al.  Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  L. F. Fajardo.  Special Report The Complexity of Endothelial Cells: A Review , 1989 .

[118]  S. Bielack,et al.  Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. , 1989, European journal of cancer & clinical oncology.

[119]  A. Burger,et al.  5-Fluorouracil-induced coronary vasospasm. , 1987, American heart journal.

[120]  L. Einhorn,et al.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.

[121]  P. Moseley,et al.  Augmentation of fibroblast proliferation by bleomycin. , 1986, The Journal of clinical investigation.

[122]  M. Ratain,et al.  Phase I and pharmacological study of vinblastine by prolonged continuous infusion. , 1986, Cancer research.

[123]  J. Hainsworth,et al.  Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. , 1986, Annals of internal medicine.

[124]  F. Muggia,et al.  Apparent myocardial ischemia associated with vinblastine administration. , 1986, Cancer treatment reports.

[125]  C. Logothetis,et al.  Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. , 1985, Cancer treatment reports.

[126]  E. Bruera,et al.  Vinca alkaloid-induced cardiovascular autonomic neuropathy. , 1985, Cancer treatment reports.

[127]  J. Lokich,et al.  Protracted vinblastine infusion: Phase I—II study in malignant melanoma and other tumors , 1984, American journal of clinical oncology.

[128]  J. Denekamp,et al.  Endothelial proliferation in tumours and normal tissues: continuous labelling studies. , 1984, British Journal of Cancer.

[129]  N. Vogelzang,et al.  Renal vascular lesions after chemotherapy with vinblastine, bleomycin, and cisplatin. , 1982, The American journal of medicine.

[130]  G. Bosl,et al.  Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. , 1981, Annals of internal medicine.

[131]  A. Castaigne,et al.  MYOCARDIAL INFARCTION FOLLOWING VINBLASTINE TREATMENT , 1980, The Lancet.

[132]  R. Owellen,et al.  Pharmacokinetics and metabolism of vinblastine in humans. , 1977, Cancer research.

[133]  I. Adamson.  Pulmonary toxicity of bleomycin. , 1976, Environmental health perspectives.

[134]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[135]  T. Nomura,et al.  Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses , 2004, Cancer Chemotherapy and Pharmacology.

[136]  K. Wierzba,et al.  γ-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor , 2004, Angiogenesis.

[137]  N. Vogelzang,et al.  Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy , 2004, Cancer Chemotherapy and Pharmacology.

[138]  P. Lønning,et al.  Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer , 2004, Cancer Chemotherapy and Pharmacology.

[139]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  C. Betsholtz,et al.  Analysis of Mural Cell Recruitment to Tumor Vessels , 2002, Circulation.

[141]  Barbara Mayer,et al.  Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[142]  M. Cumming,et al.  Antiangiogenic potential of camptothecin and topotecan , 1999, Cancer Chemotherapy and Pharmacology.

[143]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. , 1999, Current topics in microbiology and immunology.

[144]  M. Buyse,et al.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  R. D'Amato,et al.  Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. , 1997, Cancer research.

[146]  Zafrani Es.  [Drug-induced vascular lesions of the liver]. , 1993 .

[147]  P. Burri,et al.  Intussusceptive microvascular growth: a common alternative to capillary sprouting. , 1992, Archives of histology and cytology.

[148]  A. Yoshimura,et al.  Angiogenic factor , 1992, Nature.

[149]  G. Hortobagyi,et al.  Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma , 1989, Cancer.

[150]  J. Moake,et al.  Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. , 1985, Oncology.